SEC Form S-8 filed by SAB Biotherapeutics Inc.
As filed with the Securities and Exchange Commission on August 12, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
SAB Biotherapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
85-3899721 |
(State or other jurisdiction of |
|
(I.R.S. Employer |
|
|
|
777 W 41st St., Suite 401 |
|
|
Miami Beach, Florida |
|
33140 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
SAB Biotherapeutics, Inc. 2021 Omnibus Equity Incentive Plan,
As Amended
(Full title of the plans)
Samuel J. Reich
Chief Executive Officer
SAB Biotherapeutics, Inc.
777 W 41st St., Suite 401
Miami Beach, Florida 33140
(Name and address of agent for service)
(305)-845-2813
(Telephone number, including area code, of agent for service)
Copies to:
|
Ilan Katz, Esq. Brian Lee, Esq. Dentons US LLP 1221 Avenue of the Americas New York, New York 10020 Tel: (212) 768-6700 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
Large accelerated filer ☐ |
|
Accelerated filer ☐ |
Non-accelerated filer ☒ |
|
Smaller reporting company ☒ |
|
|
Emerging growth company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
SAB Biotherapeutics, Inc., a Delaware corporation (the “Registrant”) is filing this Registration Statement on Form S-8 (the “Registration Statement”) for the purpose of registering an additional 3,900,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”), issuable to eligible persons under the SAB Biotherapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, the “2021 Plan”), which shares are in addition to the shares registered on the Registrant’s registration statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on February 1, 2022 (File No. 333-262452), and the registration statement on Form S-8 filed with the Commission on February 23, 2024 (File No. 333-277314) (together, the “Prior Registration Statements”).
This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E (“General Instruction E”) to Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), regarding Registration of Additional Securities. Pursuant to General Instruction E, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2021 Plan, are incorporated herein by reference and made part of this Registration Statement, except to the extent supplemented, amended and superseded by the information set forth herein.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference
The following documents filed with the Commission by the Registrant pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated by reference into this Registration Statement:
All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement that indicates that all of the shares of Common Stock offered have been sold or that deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
3
Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.
Item 8. Exhibits.
EXHIBIT INDEX
|
|
|
Exhibit |
|
Description |
4.1 |
|
|
4.2 |
|
|
4.3 |
|
|
4.4 |
|
|
4.5 |
|
|
5.1* |
|
|
23.1* |
|
Consent of EisnerAmper LLP, independent registered public accounting firm. |
23.2* |
|
|
24.1* |
|
Power of Attorney (included on signature page of this registration statement). |
99.1* |
|
SAB Biotherapeutics, Inc. 2021 Omnibus Equity Incentive Plan, as amended. |
107* |
|
*Filed herewith.
4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Miami Beach, Florida on August 12, 2024.
SAB BIOTHERAPEUTICS, INC. |
|
By: |
/s/ Samuel J. Reich |
Name: |
Samuel J. Reich |
Title: |
Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints each of Samuel J. Reich and Lucy To as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following person in the capacities and on the date indicated below.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Samuel J. Reich |
|
Chair and Chief Executive Officer |
|
August 12, 2024 |
Samuel J. Reich |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Lucy To |
|
Chief Financial Officer |
|
August 12, 2024 |
Lucy To |
|
(Principal Financial Officer and Principal Accounting Officer) |
|
|
|
|
|
|
|
/s/ Eddie J. Sullivan, PhD |
|
President and Director |
|
August 12, 2024 |
Eddie J. Sullivan, PhD |
|
|
|
|
|
|
|
|
|
/s/ Katie Ellias |
|
Director |
|
August 12, 2024 |
Katie Ellias |
|
|
|
|
|
|
|
|
|
/s/ Christine Hamilton, MBA |
|
Director |
|
August 12, 2024 |
Christine Hamilton, MBA |
|
|
|
|
|
|
|
|
|
/s/ Scott Giberson, RPh, MPH, D.Sc. |
|
Director |
|
August 12, 2024 |
Scott Giberson, RPh, MPH, D.Sc. |
|
|
|
|
/s/ David Link, MBA |
|
Director |
|
August 12, 2024 |
David Link, MBA |
|
|
|
|
|
|
|
|
|
/s/ Erick Lucera |
|
Director |
|
August 12, 2024 |
Erick Lucera |
|
|
|
|
|
|
|
|
|
/s/ Andrew Moin |
|
Director |
|
August 12, 2024 |
Andrew Moin |
|
|
|
|
|
|
|
|
|
/s/ William Polvino, MD |
|
Director |
|
August 12, 2024 |
William Polvino, MD |
|
|
|
|
|
|
|
|
|
/s/ Jay Skyler, MD |
|
Director |
|
August 12, 2024 |
Jay Skyler, MD |
|
|
|
|
|
|
|
|
|
/s/ Jeffrey G. Spragens |
|
Director |
|
August 12, 2024 |
Jeffrey G. Spragens |
|
|
|
|